(Q36675387)

15 August 2017

1 reference

title

Kidney cancer therapy: new perspectives and avenues (English)

1 reference

15 August 2017

1 reference

Doru T Alexandrescu

1

1 reference

15 August 2017

Constantin A Dasanu

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

18

1 reference

15 August 2017

page(s)

2481-2493

1 reference

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Bevacizumab for patients with metastatic renal cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

A physiologic imaging pilot study of breast cancer treated with AZD2171.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2481

Immunotherapy for advanced renal cell cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1517/14656566.7.18.2481

1 reference

15 August 2017

1 reference